As previously shown, ICRP treatment induces caspase-independent cell death in breast cancer cells (Martínez-Torres et al., 2020[25]; Reyes-Ruiz et al., 2021[33]), however it triggers apoptosis involving caspase-3 cleavage (a principal effector caspase) on leukemic cell lines (Lorenzo-Anota et al., 2020[21]). The gene discussed is CASP3; the disease is breast carcinoma.